← Back to Company DatabaseVisit Website
Iovance Biotherapeutics
Tumor-infiltrating lymphocyte (TIL) cell therapy for cancer.
PublicSan Carlos, CAFounded 2007
About
Iovance Biotherapeutics is a biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Its lead product Amtagvi (lifileucel) is an FDA-approved TIL therapy for advanced melanoma. The company is expanding its TIL platform into additional solid tumor indications including lung and cervical cancers.
Total Funding
$1.2BKey Product
Amtagvi (lifileucel) TIL cell therapyGeography
North AmericaKey Investors
Baker BrothersRA Capital ManagementOrbiMed
Focus Areas
Treatment (Therapeutics)
Technology
Cell TherapyImmunotherapy
Cancer Types
SkinLungPan-cancer
Last updated: Feb 4, 2026